Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 10/20 | 0.49 |
| ▸ | DHFR | P00374 | 7/20 | 0.49 |
| ▸ | TYMS | P04818 | 6/20 | 0.49 |
| ▸ | FOLR2 | P14207 | 4/20 | 0.49 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.49 |
| ▸ | ATIC | P31939 | 3/20 | 0.49 |
| ▸ | SLC46A1 | Q96NT5 | 3/20 | 0.49 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.49 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.49 |
| ▸ | FRK | P42685 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370807 | 0.91 | GART (0.59) | GARTDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL17776089 | 0.84 | GART (0.66) | GARTDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL13972567 | 0.84 | TYMS (0.48) | GARTDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL13006994 | 0.81 | GART (0.59) | GARTDHFRTYMSFOLR2FOLR1 | |
| Pemetrexed SCHEMBL572065 | 0.81 | GART (0.73) | GARTDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL16480175 | 0.80 | GART (0.61) | GARTDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL27835031 | 0.79 | DHFR (0.57) | GARTDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL371409 | 0.79 | DHFR (0.57) | GARTDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL13003773 | 0.79 | GART (0.51) | GARTDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL23544600 | 0.79 | GART (0.65) | GARTDHFRTYMSFOLR2FOLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718829-B2 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | SICOR INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170129900-A1 | Crystalline Forms Of Pemetrexed Diacid And Processes For The Preparation Thereof | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2017-05-11 | — | — | US | disclosed |
| US-9562050-B2 | Crystalline forms of pemetrexed diacid and processes for the preparation thereof | SICOR, INC. (US) | 2017-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129900-A1 | Crystalline Forms Of Pemetrexed Diacid And Processes For The Preparation Thereof | DCTD, DPYD, DHFR | GART 34/4885DHFR 3/4885TYMS 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.